Logo

SLSN

Solesence, Inc. Common Stock

SLSN

Solesence, Inc. Common Stock • NASDAQ
$2.29 ▲ 5.53% (+0.12)
Market Cap $161.53 M
52w High $16.56
52w Low $1.34
Dividend Yield 0%
P/E 229
Volume 9.80K
Outstanding Shares 70.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $14.597M ▼ $4.151M ▲ $-1.12M ▼ -7.673% ▼ $-0.02 ▼ $-556K ▼
Q2-2025 $20.359M ▲ $3.967M ▲ $2.667M ▲ 13.1% ▲ $0.039 ▲ $3.369M ▲
Q1-2025 $14.625M ▲ $3.126M ▲ $80K ▲ 0.547% ▲ $0.001 ▲ $482K ▲
Q4-2024 $12.567M ▼ $2.989M ▲ $-558K ▼ -4.44% ▼ $-0.008 ▼ $5K ▼
Q3-2024 $16.866M $2.904M $3.045M 18.054% $0.04 $3.429M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $429K ▼ $53.987M ▼ $36.76M ▼ $17.227M ▼
Q2-2025 $4.108M ▲ $59.956M ▲ $41.768M ▼ $18.188M ▲
Q1-2025 $1.817M ▲ $57.016M ▲ $41.86M ▲ $15.156M ▲
Q4-2024 $1.409M ▼ $50.002M ▲ $35.056M ▲ $14.946M ▼
Q3-2024 $2.925M $48.047M $32.878M $15.169M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.12M ▼ $-2.511M ▼ $-418K ▲ $-750K ▼ $-3.679M ▼ $-2.929M ▼
Q2-2025 $2.667M ▲ $-654K ▲ $-1.408M ▼ $4.353M ▼ $2.291M ▲ $-654K ▲
Q1-2025 $80K ▲ $-7.221M ▼ $133K ▲ $7.496M ▲ $408K ▲ $-7.221M ▼
Q4-2024 $-558K ▼ $2.189M ▼ $-2.593M ▼ $-1.112M ▲ $-1.516M ▼ $-404K ▼
Q3-2024 $3.046M $4.202M $-1.403M $-2.232M $567K $2.799M

Revenue by Products

Product Q3-2024Q4-2024Q2-2025Q3-2025
Advanced Materials
Advanced Materials
 $0 ▲$0 ▲$0 ▲$0 ▲
Consumer Products
Consumer Products
 $0 ▲$0 ▲$20.00M ▲$10.00M ▼
Personal Care ingredients
Personal Care ingredients
 $0 ▲$0 ▲$0 ▲$0 ▲
Solesence
Solesence
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Solesence looks like a very small but gradually growing business that has been operating close to break-even. Revenue has edged up each year, and profitability metrics have improved from roughly flat operating results to slightly positive performance most recently. Net income and earnings per share have bounced around the zero line, which is typical for an early-stage company where even small changes in sales, costs, or one-time items can swing reported profit. Overall, the income statement points to a company that is moving in the right direction on profitability, but still operating at a scale where results are fragile and not yet firmly established.

Balance Sheet

Balance Sheet The balance sheet shows a modest asset base and a capital structure that relies meaningfully on debt relative to equity. Assets have grown a bit, suggesting investment into the business, but reported cash balances are minimal in the data provided, which may reflect either reporting classification choices or a tight liquidity position. Equity has been thin and uneven over time, which is common for smaller, transitioning companies. In simple terms, Solesence appears financially lean, with limited buffer against shocks, and will likely need continued careful management of debt, equity, and working capital as it scales.

Cash Flow

Cash Flow Cash flow information is very limited in the data provided, with operating cash flow, free cash flow, and capital spending all near neutral. This could mean the company has been close to cash break-even, or that details are not fully captured in this summary. Either way, investors and stakeholders should treat cash generation and liquidity as a key uncertainty and focus area, especially for a small manufacturer investing in innovation and growth. The company’s ability to convert its improving income statement into steady, positive cash flow is not yet clear from the figures shown.

Competitive Edge

Competitive Edge Solesence occupies a focused niche in mineral-based sun and skin protection, with a business-to-business model that supplies advanced formulas to other beauty brands. Its main strengths are patented technologies that reduce the traditional white cast of mineral sunscreens, improve cosmetic elegance, and address environmental stressors like pollution and blue light. This directly tackles long-standing consumer complaints about mineral SPF, especially for darker skin tones, and aligns with strong trends in clean, inclusive, and multifunctional beauty. The B2B partnership model lets Solesence plug into many brands and benefit from industry-wide demand. On the other hand, the company operates in a crowded global beauty and ingredients market with very large, well-funded competitors, and depends heavily on partner brands to market its technology effectively. Its competitive edge looks real and differentiated, but still needs to be proven at larger scale and across economic cycles.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Solesence’s story. The company has built a suite of patented platforms—such as Active Stress Defense, Kleair, and Blüm—that go beyond basic sun protection to address broader environmental and blue-light damage, while improving texture and appearance on the skin. These technologies are protected by intellectual property in multiple countries, and the firm is extending its reach into areas like skin healing and advanced antioxidants. The R&D strategy emphasizes ready-to-launch formulas and custom collaboration, which helps brands move quickly and stay on trend. The flip side is that sustained innovation demands ongoing investment, regulatory navigation in sun care, and continuous proof that these technologies deliver visible benefits that consumers are willing to pay for. The long-term payoff from this R&D engine will depend on how well Solesence and its partners commercialize the science.

Summary

Solesence is an early-stage, science-driven player in the beauty and personal care space, with a particular focus on mineral-based sun protection that is more elegant, inclusive, and “clean” than traditional options. Its financial profile is that of a small company progressing toward sustainable profitability but still operating close to break-even, with a lean balance sheet and limited visible cash flow history. Strategically, its edge lies in patented technology, a flexible B2B model, and strong alignment with major industry trends like clean beauty, skin health, and the blending of skincare with makeup. At the same time, its small scale, reliance on partners, and modest financial cushions introduce meaningful execution and funding risks. The recent rebranding, leadership changes, and Nasdaq uplisting suggest a company in transition, attempting to convert scientific know-how and niche leadership into broader commercial and financial traction over the coming years.

NEWS

November 11, 2025 · 7:00 AM UTC

Solésence Reports Third Quarter 2025 Financial Results

Read more

November 10, 2025 · 8:00 AM UTC

Solésence, Inc. Appoints Yoana Dvorzsak as Vice President of Innovation and Product Integrity

Read more

October 30, 2025 · 8:00 AM UTC

Solésence To Report Third Quarter 2025 Financial Results and Host a Conference Call

Read more

September 3, 2025 · 8:00 AM UTC

Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth

Read more